Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(80.0%)

Phase 1

1(20.0%)

5Total

Phase 2(4)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06561997Completed

Enhancing Thoracolumbar Burst Fracture Treatment

Role: lead

NCT06124170Completed

Improved Pain Management in Knee Osteoarthritis-related Surgeries

Role: lead

NCT05940064Phase 2Unknown

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Role: lead

NCT05940051Phase 2Unknown

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Role: lead

NCT05816694Phase 2Not Yet Recruiting

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

Role: lead

NCT03706547Phase 1Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Role: lead

NCT03605056Phase 2Unknown

Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

Role: lead

All 7 trials loaded